26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)-Reference-Cited by-同舟云学术

26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)

Published:2022-10-01 Issue:8 Volume:32 Page:453-458
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Atkinson Sarah¹,Bachinsky Mary²,Raiter Yaron³,Abreu Paula⁴,Ianos Claudia⁵,Chappell Phillip²^ORCID,Findling Robert L.⁶

Affiliation:

1. Psychiatry, Child and Adolescent Psychiatry, Finger Lakes Clinical Research, Rochester, New York, USA.

2. Clinical Development and Operations, Pfizer, Inc., Groton, Connecticut, USA.

3. Clinical Development, GE Healthcare, Eindhoven, The Netherlands.

4. Global Biometrics and Data Management, Pfizer, Inc., New York, New York, USA.

5. Worldwide Medical and Safety, Pfizer AG, Zurich, Switzerland.

6. Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/cap.2022.0030

Reference24 articles.

1. A Rating Scale for Drug-Induced Akathisia

2. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

3. A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania

4. Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study